Arthritis drugs showcase how US drug prices disregard economics

Arthritis drugs available are a costly affair to ameliorate rheumatoid arthritis. Her entire family which involves her husband, son and daughter all possess this excruciating damaging autoimmune disease and the family’s economics is consumed by paying for them.


Bower’s family even with insurance, last year encountered $600 a month in defrayment for the drug, along with supplementary payments on another $16,000 in medical bills actualized in 2016 when the erstwhile insurer declined to involve all the doses her 9-year-old daughter required.

Bowers said her family tries to recompense with prices by curbing on her children’s sports and extracurricular activities disregarding family vacations. She is employed as a part time teacher as well. However, she said that monetarily it’s a tough time and the costs should not sky rocket.

Wholesale prices for Humira and Enbrel,   frequently utilized cures for rheumatoid arthritis, known as RA, rose more than 70 percent in the last three years. Since then a lot of new medicines have been added and arrived in the market. If the fundamental economics persist, RA treatments and patients would have profited from competition, but due to the industry estimating practices, legitimate challenges and marketing strategy they haven’t. The first RA drug was priced $10,000 a year. It now has jumped to more than $40,000 — even as options have entered the U.S. market.

Peter Bach, director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes said that competition usually doesn’t function to reduce prices in branded specialty drugs.